Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience: JPN logoLink to Journal of Psychiatry & Neuroscience: JPN
. 1995 May;20(3):193–198.

Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.

J C Pecknold 1, L Luthe 1, L Iny 1, D Ramdoyal 1
PMCID: PMC1188684  PMID: 7786880

Abstract

Serotonergic implication in panic disorder has been demonstrated by the efficacy of serotonin reuptake blockers in treatment. Fluoxetine, a potent 5-HT reuptake blocker, has been suggested to have anti-panic efficacy. This open study examines 30 patients (eight males and 22 females) with an average age of 36.9 years, ranging from 18 to 62, who were treated for eight weeks with fluoxetine (mean dose 20 mg per day). All patients fulfilled DSM-III-R criteria of panic disorder with agoraphobia as determined in a SCID interview schedule. Out of 28 patients who started medication, 64% of the patients completed the clinical trial and 36% of the patients dropped out of treatment because of increased anxiety or a lack of efficacy. Thirty-two percent of the patients had zero panic attacks by week 3. By the end of eight weeks of treatment, 48% of the patients had zero panic attacks. There was a significant reduction in anxiety and phobic avoidance and panic attacks. Tritiated platelet imipramine and paroxetine bindings revealed significantly lower maximal binding for patients with panic disorder in comparison with controls. Paroxetine Bmax showed a trend to increase in the direction of control values by the end of the trial.

Full text

PDF
193

Images in this article

196Fig.1
on p.196
197Fig.2
on p.197

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballenger J. C., Burrows G. D., DuPont R. L., Jr, Lesser I. M., Noyes R., Jr, Pecknold J. C., Rifkin A., Swinson R. P. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May;45(5):413–422. doi: 10.1001/archpsyc.1988.01800290027004. [DOI] [PubMed] [Google Scholar]
  2. Ballenger J. C. Pharmacotherapy of the panic disorders. J Clin Psychiatry. 1986 Jun;47 (Suppl):27–32. [PubMed] [Google Scholar]
  3. Blakely R. D., Berson H. E., Fremeau R. T., Jr, Caron M. G., Peek M. M., Prince H. K., Bradley C. C. Cloning and expression of a functional serotonin transporter from rat brain. Nature. 1991 Nov 7;354(6348):66–70. doi: 10.1038/354066a0. [DOI] [PubMed] [Google Scholar]
  4. Briley M. S., Langer S. Z., Raisman R., Sechter D., Zarifian E. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science. 1980 Jul 11;209(4453):303–305. doi: 10.1126/science.7384806. [DOI] [PubMed] [Google Scholar]
  5. Briley M. S., Raisman R., Sechter D., Zarifian E., Langer S. Z. [3H]-Imipramine binding in human platelets: a new biochemical parameter in depression. Neuropharmacology. 1980 Dec;19(12):1209–1210. doi: 10.1016/0028-3908(80)90204-x. [DOI] [PubMed] [Google Scholar]
  6. Charney D. S., Woods S. W., Goodman W. K., Rifkin B., Kinch M., Aiken B., Quadrino L. M., Heninger G. R. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986 Dec;47(12):580–586. [PubMed] [Google Scholar]
  7. Da Prada M., Cesura A. M., Launay J. M., Richards J. G. Platelets as a model for neurones? Experientia. 1988 Feb 15;44(2):115–126. doi: 10.1007/BF01952193. [DOI] [PubMed] [Google Scholar]
  8. Den Boer J. A., Westenberg H. G. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1988 Jan;3(1):59–74. doi: 10.1097/00004850-198801000-00005. [DOI] [PubMed] [Google Scholar]
  9. Escobar J. I., Landbloom R. P. Treatment of phobic neurosis with clomipramine: a controlled clinical trial. Curr Ther Res Clin Exp. 1976 Nov;20(5):680–685. [PubMed] [Google Scholar]
  10. Evans L., Kenardy J., Schneider P., Hoey H. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand. 1986 Jan;73(1):49–53. doi: 10.1111/j.1600-0447.1986.tb02666.x. [DOI] [PubMed] [Google Scholar]
  11. Gorman J. M., Liebowitz M. R., Fyer A. J., Goetz D., Campeas R. B., Fyer M. R., Davies S. O., Klein D. F. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987 Oct;7(5):329–332. [PubMed] [Google Scholar]
  12. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hoffman B. J., Mezey E., Brownstein M. J. Cloning of a serotonin transporter affected by antidepressants. Science. 1991 Oct 25;254(5031):579–580. doi: 10.1126/science.1948036. [DOI] [PubMed] [Google Scholar]
  14. Iny L. J., Pecknold J., Suranyi-Cadotte B. E., Bernier B., Luthe L., Nair N. P., Meaney M. J. Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry. 1994 Sep 1;36(5):281–291. doi: 10.1016/0006-3223(94)90625-4. [DOI] [PubMed] [Google Scholar]
  15. Johnston D. G., Troyer I. E., Whitsett S. F. Clomipramine treatment of agoraphobic women. An eight-week controlled trial. Arch Gen Psychiatry. 1988 May;45(5):453–459. doi: 10.1001/archpsyc.1988.01800290073009. [DOI] [PubMed] [Google Scholar]
  16. Kahn R. S., Westenberg H. G., Verhoeven W. M., Gispen-de Wied C. C., Kamerbeek W. D. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol. 1987 Jan;2(1):33–45. doi: 10.1097/00004850-198701000-00003. [DOI] [PubMed] [Google Scholar]
  17. Marks I. M., Mathews A. M. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263–267. doi: 10.1016/0005-7967(79)90041-x. [DOI] [PubMed] [Google Scholar]
  18. Mavissakalian M., Perel J. M., Michelson L. The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J Clin Psychopharmacol. 1984 Feb;4(1):36–40. [PubMed] [Google Scholar]
  19. Mavissakalian M., Perel J., Bowler K., Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987 Jun;144(6):785–787. doi: 10.1176/ajp.144.6.785. [DOI] [PubMed] [Google Scholar]
  20. Modigh K., Svensson T. H. On the role of central nervous system catecholamines and 5-hydroxytryptamine in the nialamide-induced behavioural syndrome. Br J Pharmacol. 1972 Sep;46(1):32–45. doi: 10.1111/j.1476-5381.1972.tb06846.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pecknold J. C., McClure D. J., Appeltauer L., Allan T., Wrzesinski L. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br J Psychiatry. 1982 May;140:484–490. doi: 10.1192/bjp.140.5.484. [DOI] [PubMed] [Google Scholar]
  22. Perry E. K., Marshall E. F., Blessed G., Tomlinson B. E., Perry R. H. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry. 1983 Feb;142:188–192. doi: 10.1192/bjp.142.2.188. [DOI] [PubMed] [Google Scholar]
  23. Pletscher A. Platelets as models: use and limitations. Experientia. 1988 Feb 15;44(2):152–155. doi: 10.1007/BF01952200. [DOI] [PubMed] [Google Scholar]
  24. Schneier F. R., Liebowitz M. R., Davies S. O., Fairbanks J., Hollander E., Campeas R., Klein D. F. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990 Apr;10(2):119–121. doi: 10.1097/00004714-199004000-00007. [DOI] [PubMed] [Google Scholar]
  25. Solyom L., Solyom C. A. Successful fluvoxamine treatment of a case of refractory obsessive-compulsive disorder. Can J Psychiatry. 1990 Nov;35(8):696–698. doi: 10.1177/070674379003500810. [DOI] [PubMed] [Google Scholar]
  26. Stanley M., Virgilio J., Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982 Jun 18;216(4552):1337–1339. doi: 10.1126/science.7079769. [DOI] [PubMed] [Google Scholar]
  27. den Boer J. A., Westenberg H. G., Kamerbeek W. D., Verhoeven W. M., Kahn R. S. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol. 1987 Jan;2(1):21–32. doi: 10.1097/00004850-198701000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES